Published by BioAgilytix
Traditional clinical markers of kidney injury, such as BUN and serum creatinine, lack sufficient sensitivity for early detection of injury and are not specific for the site of injury; thus, they have limited clinical utility. Site-specific nephrotoxicity biomarkers can be used to detect early stage renal injury and to localize that injury to specific sites within the kidney.
The purpose of this study was to evaluate two 96-well multiplex electrochemiluminescent immunoassays from MSD (Meso Scale Discovery) which quantitatively measure the levels of biomarkers of kidney toxicity in rats. The Kidney Injury Panel 1 Assay measures lipocalin-2 (NGAL), osteopontin, albumin, and TIM-1/KIM-1/HAVCR, and the Acute Kidney Injury (AKI) panel measures the levels of alpha GST, GSTYb1 and RPA-1 in rat urine as indicators of renal damage.